INVO Fertility Q2 2026 Earnings Report

INVO Fertility EPS Results

• Actual EPS: $0.35
• Consensus EPS: N/A
• Beat/Miss: N/A
• One Year Ago EPS: N/A

INVO Fertility Revenue Results

• Actual Revenue: $2.18 million
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

INVO Fertility Announcement Details

• Quarter: Q2 2026
• Date: 8/14/2026
• Time: After Market Closes
• Conference Call Date: N/A
• Conference Call Time: N/A

INVO Fertility (NASDAQ:IVF). is a medical technology and fertility services company focused on expanding access to in vitro fertilization (IVF) and related assisted reproductive technologies. The company’s primary product is INVOcell, an intravaginal culture system designed to incubate eggs and embryos inside a woman’s body during part of the IVF process, under the supervision of a fertility professional.

INVO Fertility seeks to make fertility treatment more accessible through a combination of medical devices, clinical services, and fertility centers. Its business model includes commercializing INVOcell, supporting clinics that use the technology, and developing or operating fertility treatment centers that provide services such as evaluation, egg retrieval, embryo culture, and embryo transfer.

The company was formerly known as INVO Bioscience and adopted the INVO Fertility name as it expanded its focus beyond device commercialization toward a broader fertility-care platform. INVOcell has received regulatory clearance in the United States and is also marketed in selected international markets, subject to applicable regulatory requirements. The company’s activities have primarily centered on the United States, with additional commercial and clinical opportunities pursued internationally.